Every parliamentary written question tabled by Cameron Thomas this session, with the full answer and department. See how every department answers, or back to the MP page.
Showing 61–80 of 94 · Department of Health and Social Care
If he will take steps to include provisions relating to the treatment and care of people with eating disorders in the forthcoming modern service framework for mental health.
The exact scope of the modern service framework for people with severe mental illness is currently under development with external stakeholders, but we expect that it will include care and treatment for people with eating disorders.
Whether he is taking steps to ensure accountability for the equitable provision of palliative care.
Palliative care services are included in the list of services an integrated care board (ICB) must commission. To support ICBs in this duty, NHS England has published statutory guidance and service specifications. The statutory guidance states that ICBs must work to ensure that there is sufficient provision of care services to meet the needs of their local populations. NHS England has also developed a palliative care and end of life care dashboard, which brings together all relevant local data in one place. The dashboard helps commissioners understand the palliative care and end of life care needs of their local population, enabling ICBs to put plans in place to address and track the improvement of health inequalities, and ensure that funding is distributed fairly, based on prevalence. The Department and NHS England are currently looking at how to improve the access, quality, and sustainability of all-age palliative care and end of life care in line with the 10-Year Health Plan.We will closely monitor the shift towards the strategic commissioning of palliative care and end of life care services to ensure that services reduce variation in access and quality, although some variation may be appropriate to reflect both innovation and the needs of local populations.Additionally, through the National Institute for Health and Care Research, the Department is investing £3 million in a new Policy Research Unit in Palliative and End of Life Care. This unit launched in January 2024 and is building the evidence base on palliative care and end of life care, with a specific focus on inequalities.On ICB accountability, NHS England has a legal duty to annually assess the performance of each ICB in respect of each financial year and to publish a summary of its findings. This assessment must assess how well the ICB has discharged its functions.
If he will make it his policy to extend the eligibility criteria for the covid-19 vaccine to include people with asthma.
The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). The primary aim of the national COVID-19 vaccination programme remains the prevention of serious illness (hospitalisations and deaths) arising from COVID-19. Population immunity to COVID-19 has been increasing due to a combination of naturally acquired immunity following recovery from infection and vaccine-derived immunity. COVID-19 is now a relatively mild disease for most people, though it can still be unpleasant, with rates of hospitalisation and death from COVID-19 having reduced significantly since COVID-19 first emerged.The focus of the JCVI advised programme has therefore moved towards targeted vaccination of the two groups who continue to be at higher risk of serious disease, including mortality. These are the oldest adults and individuals who are immunosuppressed.On 13 November 2024, JCVI published advice on who should be offered vaccination in autumn 2025. On 26 June 2025, the Government accepted the JCVI’s advice that in autumn 2025, a COVID-19 vaccination should be offered to the following groups:adults aged 75 years and over;residents in care homes for older adults;individuals aged 6 months and over who are immunosuppressed (as defined in the ‘immunosuppression’ sections of tables 3 or 4 in the COVID-19 chapter of the UK Health Security Agency Green Book).The Government has no plans to change eligibility for autumn 2025. It has accepted the JCVI advice for this campaign in full. As for all vaccines, the JCVI keeps the evidence under regular review.
What steps his Department is taking to help increase capacity in phlebotomy services.
Blood tests are among the most commonly requested diagnostic investigations across primary and secondary care, and they are readily available across all 27 National Health Service pathology networks. Phlebotomy – the procedure to collect blood samples – is widely available across general practice, community health services, and secondary care phlebotomy clinics, supporting equitable access to blood testing. Where phlebotomy services are provided by general practice, they are commissioned locally by integrated care boards (ICBs). ICBs are responsible for commissioning phlebotomy services based on local population need and are funded for these services as part of their annual funding allocations. In January 2025, we published the Elective Reform Plan, which sets out the productivity and reform efforts needed to return to the 18-week constitutional standard by the end of this parliament. The Plan commits to transform and expand diagnostic services and speed up waiting times for tests, a crucial part of reducing overall waiting times. Community Diagnostic Centres (CDCs), including those in Gloucestershire and Herefordshire, are supporting one of the governments key strategic shifts – moving care from the hospital to the community. CDCs offer local populations a wide range of diagnostic tests, including phlebotomy, closer to home and greater choice on where and how they are undertaken.We are continuing to invest in expanding diagnostic capacity in the NHS. As set out in the Elective Reform Plan, we plan to build up to five more CDCs in 2025/26, alongside increasing the operating hours of existing sites so that more offer services 12 hours a day, seven days a week. This is backed by part of the £600 million of capital investment for diagnostic services announced at the October 2024 Spending Review.
What steps he is taking to ensure equality of access to tofersen by people diagnosed with SOD1 motor neurone disease across England.
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. The NHS in England is legally required to fund medicines recommended by NICE, normally within three months of the publication of final guidance.NICE has selected tofersen for treating amyotrophic lateral sclerosis caused by the superoxide dismutase – 1 (SOD1) gene mutations as a topic for guidance development through its Highly Specialised Technology (HST) programme. The HST programme appraises medicines for the treatment of very rare, and often very severe diseases, and evaluates whether they can be considered a clinically and cost-effective use of NHS resources. NICE has not yet been able to start the evaluation of tofersen as it is unable to issue guidance on the use of the technology without receiving an evidence submission about the technology’s clinical and cost-effectiveness from the marketing authorisation holder. Therefore, NICE is ready to review tofersen via its HST programme, as soon as Biogen indicates that it is ready to start the NICE evaluation.I am aware that the marketing authorisation holder has established early access programmes (EAPs) through which some patients are currently accessing tofersen. Participation in company-led schemes is decided at an individual NHS trust level and under these programmes, the cost of the drug is free to both patients taking part in it, and to the NHS, but NHS trusts must still cover the administration costs and must provide clinical resources to deliver the EAP. No assessment has been made of regional variation in access to tofersen through the programme.NHS England has published guidance for integrated care systems (ICS) on free of charge medicines schemes, providing advice on potential financial, resourcing, and clinical risks. ICSs should use the guidance to help determine whether to implement any of these schemes, including assessing suitability and any risks in the short, medium, and long term. The guidance is available at the following link:https://www.england.nhs.uk/long-read/free-of-charge-foc-medicines-schemes-national-policy-recommendations-for-local-systems/
What information his Department holds on the number of children and young adults with (a) PANS and (b) PANDAS.
Information on the number of children and young adults with paediatric acute-onset neuropsychiatric syndrome (PANS) and paediatric autoimmune neuropsychiatric disorder associated with streptococcus (PANDAS) is not collected at present as there are no internationally agreed criteria to identify these conditions. The PANS PANDAS Steering Group is currently working on a consensus for case identification to support a national survey. Due to the emerging nature of the evidence base there is currently a lack of consensus on what good clinical practice and training on PANS and PANDAS may look like, and no assessments have therefore been made.
If he will make an assessment of the adequacy of the the availability of training programmes on (a) PANS and (b) PANDAS for NHS staff.
Information on the number of children and young adults with paediatric acute-onset neuropsychiatric syndrome (PANS) and paediatric autoimmune neuropsychiatric disorder associated with streptococcus (PANDAS) is not collected at present as there are no internationally agreed criteria to identify these conditions. The PANS PANDAS Steering Group is currently working on a consensus for case identification to support a national survey. Due to the emerging nature of the evidence base there is currently a lack of consensus on what good clinical practice and training on PANS and PANDAS may look like, and no assessments have therefore been made.
What recent assessment his Department has made of the adequacy of the provision of (a) treatment and (b) care for children and young adults with (i) PANS and (ii) PANDAS.
Information on the number of children and young adults with paediatric acute-onset neuropsychiatric syndrome (PANS) and paediatric autoimmune neuropsychiatric disorder associated with streptococcus (PANDAS) is not collected at present as there are no internationally agreed criteria to identify these conditions. The PANS PANDAS Steering Group is currently working on a consensus for case identification to support a national survey. Due to the emerging nature of the evidence base there is currently a lack of consensus on what good clinical practice and training on PANS and PANDAS may look like, and no assessments have therefore been made.
If he will hold discussions with the National Institute for Health and Care Excellence on the development of guidelines for PANS and PANDAS.
Decisions on topics for new or updated guidance from the National Institute for Health and Care Excellence (NICE) are considered through an established NICE prioritisation process with decisions overseen by a prioritisation board, chaired by NICE’s Chief Medical Officer.NICE’s prioritisation board considered the development of guidance on paediatric acute-onset neuropsychiatric syndrome and paediatric autoimmune neuropsychiatric disorder associated with streptococcus in November 2024 and concluded that there is insufficient evidence in this area to develop useful guidance.
What steps his Department is taking to reduce geographical cost differences for (a) abiraterone and (b) similar drugs in England.
The procurement of abiraterone for secondary care is currently part of NHS England’s generic wave tender structure. NHS England tenders two regions out of six at a time to encourage competition and to ensure supply chain resilience, awarding the top two compliant suppliers onto the framework each time. Prices may vary between regions, but within NHS England’s terms and conditions there is a price review mechanism whereby any price changes can be matched/applied in other regions. Also, within the tender there is a price limiter criterion which is applied so that only bids that are in line with market norms will be compliant.
What steps his Department is taking to ensure that veterans who leave the armed forces can access NHS dental care.
We are working to improve access to National Health Service dentistry, which will also benefit our valued members of the Armed Forces community, including our respected veterans who have spent their careers defending our country.We are committed to reforming the dental contract, with a shift to focus on prevention and the retention of NHS dentists. The Government’s ambition is to deliver fundamental contract reform before the end of this Parliament. Veterans will be able to benefit from the improved access these changes bring.We are also supporting more than 1,500 children in British military families overseas through our supervised toothbrushing programme. Free NHS dental care is available to people who meet the following criteria:under 18 years old, or under 19 years old and in full-time education;pregnant or have had a baby in the previous 12 months;being treated in an NHS hospital and the treatment is carried out by the hospital dentist, although patients may have to pay for any dentures or bridges;receiving low-income benefits, or under 20 years old and a dependant of someone receiving low-income benefits; and/orreceiving War Pension Scheme payments, or Armed Forces Compensation Scheme payments and the treatment is for your accepted disability.
What recent assessment his Department has made of the geographic differences in the cost of abiraterone for high-risk prostate cancer patients in England.
The procurement of abiraterone for secondary care is currently part of NHS England’s generic wave tender structure. NHS England tenders two regions out of six at a time to encourage competition and to ensure supply chain resilience, awarding the top two compliant suppliers onto the framework each time. Prices may vary between regions, but within NHS England’s terms and conditions there is a price review mechanism whereby any price changes can be matched/applied in other regions. Also, within the tender there is a price limiter criterion which is applied so that only bids that are in line with market norms will be compliant.
What steps his Department is taking to expand dental services in rural areas.
We are aware of the challenges faced in accessing a dentist, particularly in more rural areas.The responsibility for commissioning primary care services, including National Health Service dentistry, to meet the needs of the local population has been delegated to integrated care boards (ICBs) across England.ICBs are recruiting posts through the Golden Hello scheme. This recruitment incentive will see dentists receiving payments of £20,000 to work in those areas that need them most for three years.We are committed to reforming the dental contract, with a shift to focus on prevention and the retention of NHS dentists. The Government’s ambition is to deliver fundamental contract reform before the end of this Parliament.
What steps his Department is taking to ensure that elderly people have reliable access to dental care.
The responsibility for commissioning primary care services, including National Health Service dentistry, to meet the needs of the local population has been delegated to integrated care boards (ICBs) across England. This includes considering the needs of elderly populations. The ICB for the Tewkesbury constituency is Gloucestershire ICB.We know that as people age, they tend to move to rural and coastal areas where the challenges in accessing NHS dentistry are exacerbated. We have introduced the Golden Hellos scheme which will see dentists receiving payments of £20,000 to work in those areas that need them most for three years.ICBs may commission specialised dental services including domiciliary care for elderly people living in care homes. The National Institute for Health and Care Excellence (NICE) guideline on oral health in care homes sets out several recommendations for care homes to help maintain and improve oral health and ensure timely access to dental treatment for their residents. The Government expects care homes to be following NICE guidance and recommendations in this area.
If he will make an assessment of the potential implications for his policies of recent incidents involving known risk items being accessed by mental health patients with the knowledge of NHS staff.
On 4 April 2025, NHS England published its ‘Staying Safe from Suicide: Best Practice Guidance for Safety Assessment, Formulation and Management'. This promotes a shift towards a more holistic, person-centred approach rather than relying on risk prediction, which is unreliable because suicidal thoughts can change quickly. Instead, it recommends using a method based on understanding each person’s situation and managing their safety.The purpose of this guidance is to enable mental health practitioners to adopt best practice principles in working with people of all ages to stay safe from suicide. This guidance also has a section covering confidentiality and the law and refers to the consensus statement for information sharing and suicide prevention. The guidance is available at the following link:https://www.england.nhs.uk/long-read/staying-safe-from-suicide/Work is also underway to make training available to all mental health practitioners to incorporate the principles of this guidance into their practice. This training was recently launched and is available via an e-learning module. This complements existing local training on suicide prevention, and a number of other national e-learning products that are already available.The National Confidential Inquiry into Suicide and Safety in Mental Health has been commissioned through the NHS England Culture of Care programme to support every provider of National Health Service commissioned inpatient services to move to personalised safety planning in line with evidence.In addition to this, the Health Services Safety Investigations Body’s (HSSIB) investigation into mental health inpatient settings identified important concerns and safety recommendations that can help us to improve mental health care, protect patients and the public and create a safe working environment for staff. We are in the process of formally responding to all the recommendations for the Department made within these reports. NHS England will be publishing guidance in response to the HSSIB’s recommendations defining the therapeutic relationship and guidance on responding to the use of non-anchored ligature points.
What recent assessment he has made of the potential implications for his policies of rates of sexual assault incidents at inpatient mental health hospitals.
It is wholly unacceptable for any patient or member of staff to experience violence or harassment of any kind in National Health Service settings, and all organisations must take robust and compassionate action to prevent it. The Government is committed to supporting and challenging the system to ensure a safe environment for our staff and patients.Although no direct assessment of policy implications on rates of sexual assaults has been made, in September 2023, the Sexual Safety Charter was launched by NHS England with the aim of promoting a zero-tolerance approach towards sexual misconduct in the workplace. Every NHS trust and integrated care board (ICB) have since signed up to the Charter and are actively working to implement its ten principles to tackle unwanted, inappropriate or harmful sexual behaviour in the workplace.In October 2024, NHS England launched a new national sexual misconduct people policy framework and training to help staff right across the NHS to ensure they are taking the right steps in recognising, reporting and acting on sexual misconduct at work. The new framework outlines how those working in the health service should recognise, report and act on sexual misconduct in the workplace, against staff or patients. The framework is available at the following link:https://www.england.nhs.uk/publication/national-people-sexual-misconduct-policy-framework/NHS England is currently measuring the uptake of framework across all trusts and ICBs, including gathering key feedback about its impact and effectiveness so far. Feedback will be used to identify areas where organisations need support in implementing to achieve a sexual safety culture.Several tools and resources have been developed by NHS England for trusts and ICBs to adopt and take further actions on sexual misconduct. This includes the first-ever NHS-wide training on sexual misconduct awareness, now available to the entire workforce, including mental health staff conducting Mental Health Act Section 17 escort duties.NHS England has recently written to providers and asked them to take further steps to identify potential perpetrators of sexual misconduct and to redouble efforts to protect staff and patients.
What recent assessment he has made of rates of sexual assault incidents perpetrated by mental health staff conducting Mental Health Act Section 17 escort duties or similar protective observations.
It is wholly unacceptable for any patient or member of staff to experience violence or harassment of any kind in National Health Service settings, and all organisations must take robust and compassionate action to prevent it. The Government is committed to supporting and challenging the system to ensure a safe environment for our staff and patients.Although no direct assessment of policy implications on rates of sexual assaults has been made, in September 2023, the Sexual Safety Charter was launched by NHS England with the aim of promoting a zero-tolerance approach towards sexual misconduct in the workplace. Every NHS trust and integrated care board (ICB) have since signed up to the Charter and are actively working to implement its ten principles to tackle unwanted, inappropriate or harmful sexual behaviour in the workplace.In October 2024, NHS England launched a new national sexual misconduct people policy framework and training to help staff right across the NHS to ensure they are taking the right steps in recognising, reporting and acting on sexual misconduct at work. The new framework outlines how those working in the health service should recognise, report and act on sexual misconduct in the workplace, against staff or patients. The framework is available at the following link:https://www.england.nhs.uk/publication/national-people-sexual-misconduct-policy-framework/NHS England is currently measuring the uptake of framework across all trusts and ICBs, including gathering key feedback about its impact and effectiveness so far. Feedback will be used to identify areas where organisations need support in implementing to achieve a sexual safety culture.Several tools and resources have been developed by NHS England for trusts and ICBs to adopt and take further actions on sexual misconduct. This includes the first-ever NHS-wide training on sexual misconduct awareness, now available to the entire workforce, including mental health staff conducting Mental Health Act Section 17 escort duties.NHS England has recently written to providers and asked them to take further steps to identify potential perpetrators of sexual misconduct and to redouble efforts to protect staff and patients.
Whether his Department plans to hold discussions with leaders of mental health services on meeting the requirements of the statutory duty of candour.
The Government is supportive of the review it inherited into the effectiveness of the statutory duty of candour for health and social care providers. Our aim is to ensure that all providers, including mental health trusts, and their leaders act upon the duty consistently and effectively to improve openness, coupled with effective enforcement by the Care Quality Commission.The review included a call for evidence, and the Government published its findings on 26 November 2024. These findings are available at the following link:https://www.gov.uk/government/publications/findings-of-the-call-for-evidence-on-the-statutory-duty-of-candour/findings-of-the-call-for-evidence-on-the-statutory-duty-of-candourThe Government also launched a public consultation on 26 November 2024, on proposals to regulate National Health Service managers. This sought views on making managers, including those in mental health providers, accountable for ensuring that the statutory duty is correctly followed in their organisation. In finalising the review on the statutory duty of candour, we are considering our proposals on candour set out in the Government’s response to the consultation, which was published on 21 July 2024, and other areas including recommendations made by the Infected Blood Inquiry. The consultation response is available at the following link:https://www.gov.uk/government/consultations/leading-the-nhs-proposals-to-regulate-nhs-managers/outcome/leading-the-nhs-proposals-to-regulate-nhs-managers-consultation-response
What assessment he has made of the potential merits of increasing funding for new (a) services and (b) research to support people with (i) myalgic encephalomyelitis and (ii) chronic fatigue syndrome.
NHS England is responsible for allocating funding to integrated care boards, which in turn are responsible for commissioning specialist myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) services that meet the needs of their population, subject to local prioritisation and funding.On 22 July 2025, we published the final ME/CFS delivery plan, which is available at the following link:https://www.gov.uk/government/publications/mecfs-the-final-delivery-planWithin the plan there is an action for the Department and NHS England to explore whether a specialised service should be prescribed for very severe ME/CFS.The Government funds research through the National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC). We have assessed the ME/CFS research portfolio funded through NIHR and MRC and acknowledge that this is an under-funded area. The level of funding awarded is directly related to the number and quality of applications received and we have historically received a small number of applications for funding in this area. Between 2019/20 and 2023/24, the NIHR committed approximately £3.7 million to research projects and programmes on ME/CFS. In the same period, the MRC committed approximately £2.9 million to research into ME/CFS.Together with the MRC, we are actively exploring next steps for research in ME/CFS. In the final delivery plan for ME/CFS, we have outlined the research actions and additional support that we will offer to the research community to increase the volume and quality of applications. This includes a new funding opportunity for a development award focussed on evaluating repurposed pharmaceutical inventions for post-acute infection syndromes and associated conditions, including ME/CFS.
What recent assessment his Department has made of the adequacy of dementia care.
Our health system has struggled to support those with complex needs, including those with dementia. Under the 10-Year Health Plan, those living with dementia will benefit from improved care planning and better services.We will deliver the first ever Modern Service framework for Frailty and Dementia to deliver rapid and significant improvements in quality of care and productivity. This will be informed by phase one of the independent commission into adult social care, expected in 2026.The Government is committed to improving dementia care and empowering local leaders with the autonomy they need to provide the best services to their local community, including those with dementia.That is why we published the D100: Assessment Tool Pathway programme earlier this year, which brings together multiple resources into a single, consolidated tool. This will help simplify best practice for system leaders and help create communities and services where the best possible care and support is available to those with dementia. The D100: Pathway Assessment Tool is available at the following link:https://www.rcpsych.ac.uk/improving-care/nccmh/service-design-and-development/dementia-100-pathway-assessment-tool